GlassScriptPhysician profile
Star Michelle Roe
NPI 1790393577
$55,211.52
in general payments reported to CMS, 2019-2025
29 companies · $10K in 2025
The $10K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,133 · 2022: $3,780 · 2023: $27K · 2024: $12K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40K · Food and Beverage: $7,197 · Travel and Lodging: $1,496 · Education: $480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40,125.00 |
| Food and Beverage | $7,196.83 |
| Travel and Lodging | $1,495.89 |
| Education | $480.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $47,293.25 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $1,787.97 | 2021-2025 | |
| Harmony Biosciences LLC | $951.66 | 2022-2025 | Wakix |
| Alkermes, INC. | $713.79 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $679.31 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Axsome Therapeutics, INC. | $653.10 | 2022-2025 | Sunosi, Auvelity |
| Otsuka America Pharmaceutical, INC. | $536.40 | 2022-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $494.53 | 2021-2025 | Caplyta |
| Corium, LLC | $430.46 | 2022-2024 | Azstarys |
| Lundbeck LLC | $180.04 | 2021-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $161.88 | 2021-2024 | Trintellix |
| Glaxosmithkline, LLC. | $151.21 | 2021 | |
| Avadel Cns Pharmaceuticals, LLC | $148.82 | 2024-2025 | Lumryz |
| Biohaven Pharmaceuticals, INC. | $140.81 | 2021 | |
| Novo Nordisk INC | $137.29 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $128.72 | 2022-2025 | Ingrezza |
| Biohaven Pharmaceutical Holding Company LTD. | $118.37 | 2022 | |
| Ironshore Pharmaceuticals INC. | $88.78 | 2023 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $87.91 | 2022-2025 | Spravato |
| Sunovion Pharmaceuticals INC. | $84.71 | 2022 | |
| Vanda Pharmaceuticals INC. | $83.02 | 2021-2025 | Fanapt, Hetlioz |
| Lilly USA, LLC | $35.82 | 2025 | Zepbound, Mounjaro |
| Smith+Nephew, INC. | $32.59 | 2021 | |
| Amgen INC. | $21.37 | 2021 | |
| Pfizer INC. | $18.24 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $14.20 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.13 | 2023 | Quviviq |
| Allergan, INC. | $12.46 | 2021 | |
| Impel Pharmaceuticals INC. | $11.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Star Roe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.